Chapter 6 - The Ghost in the Holding CompanyI stared at the screen, the glowing blue light reflecting in my pupils as the pieces of a much larger, darker puzzle began to snap into place.
For years, my holding company, Foster Capital, had acquired dozens of smaller biotech and medical logistics firms. Most of them were passive investments managed by regional directors. I rarely looked at the granular operational reports unless a subsidiary posted a red flag on quarterly returns.
Sam Miller wasn't just a rogue competitor trying to undercut my logistics chain. He was a sleeper agent inside my own extended financial network.
My phone buzzed again. Frank’s voice came through the speakerphone before I even swiped to answer.
"Daniel, you seeing this?" Frank sounded breathless. "The subsidiary tied to that Boston lab—Vanguard Bio-Research—it’s not a third-party vendor. It’s a wholly-owned subsidiary of Foster Capital. It’s been funneling R&D capital through shell accounts for over four years."
"Who approved the subsidiary's charter?" I asked, my voice dangerously calm.
"Your uncle," Frank said. "Richard Foster. Before he stepped down from the board."
Richard. My father’s younger brother, who had supposedly retired to a quiet estate in Vermont after liquidating his primary assets a decade ago. For years, I had believed he was completely detached from the daily operations of the empire I had built and expanded.
"Richard has been out of the loop for a decade," I said, though even as I spoke the words, I knew how naive they sounded. Men like Richard Foster didn't retire. They just moved their operations into the shadows.
"Not according to the corporate registry," Frank corrected. "His personal holding entity still holds a five percent golden share in Vanguard Bio-Research. And Daniel... that lab in Boston isn't developing commercial therapeutics. They're doing genetic mutation trials using pediatric protein serums as a catalyst."
I stood up so fast my chair rolled backward and slammed into the wood-paneled wall.
"Catalyst for what?" I demanded.
"That's the part you're not going to like," Frank said grimly. "The trial subjects aren't lab animals. They're children. Children from low-income families whose medical debt was bought out by Vanguard's front companies over the past six years. Children like Lily Santos."
The blood in my veins turned to ice.
May you like
Maya wasn't just an unlucky housekeeper caught in the crossfire of corporate greed. Her daughter’s rare respiratory condition wasn't a natural affliction—it was the baseline symptom of an experimental genetic sequence that had been administered to children in municipal clinics under the guise of routine immunization programs.
And my own company's capital had been used to fund the laboratory that created it.
